Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064402 · ClinicalTrials.gov registry record · Phase 3
Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD
A Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 741
- Enrollment target
- 20
- Study locations
NCT00064402 is a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema that has completed, run by Sumitomo Pharma America. The registered enrollment target is 741 participants, below the 1,745-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00064402, a Phase 3 study of Chronic Obstructive Pulmonary Disease and Emphysema, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 741 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Salmeterol
- DRUG arformoterol tartrate inhalation solution
Study Locations (20)
California
- Northern California Research Corp. - Fair Oaks
- SARC Research Center - Fresno
- California Research Medical Group, Inc. - Fullerton
- Radiant Research-Irvine - Irvine
- West Coast Clinical Trials - Newport Beach
- Center for Clinical Trials, LLC - Paramount
- Advances in Medicine - Rancho Mirage
- Institute of Healthcare Assessment, Inc. - San Diego
- San Jose Clinical Research - San Jose
- Allergy & Asthma Medical Group of Diablo Valley, Inc. - Walnut Creek
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- University Clinical Research, DeLand - DeLand
- Mt. Sinai Medical Center - Miami Beach
Arizona
- Pulmonary Associates, PA - Phoenix
- Arizona Clinical Research Center, Inc. - Tucson
Colorado
- Colorado Pulmonary Associates - Denver
- Northern Colorado Pulmonary Consultants, PC - Fort Collins
Alabama
- Pulmonary & Sleep Associates of Jasper, PC - Jasper
Connecticut
- Physicians Research Center, Inc. - Hartford
District of Columbia
- Washington Hospital Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 741 participants |
| Start Date | 2002-04 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064402
The ClinicalTrials.gov registry entry for NCT00064402 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 741 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,745-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (58% lower). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00064402 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00064402 about?
NCT00064402 is a clinical study titled "Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD". The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD
What is the current status of trial NCT00064402?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 741 participants. The study started on 2002-04. Estimated completion is 2004-03.
What conditions does trial NCT00064402 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, Emphysema, Chronic Bronchitis.
What interventions are being tested in trial NCT00064402?
The interventions under investigation include: Placebo (DRUG), Salmeterol (DRUG), arformoterol tartrate inhalation solution (DRUG).
Who is sponsoring clinical trial NCT00064402?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00064402 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.